- Home
- BFS vs ABUS Comparison
BFS vs ABUS Comparison
Compare BFS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFS
- ABUS
- Stock Information
- Founded
- BFS 1993
- ABUS 2005
- Country
- BFS United States
- ABUS United States
- Employees
- BFS N/A
- ABUS N/A
- Industry
- BFS Real Estate Investment Trusts
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- BFS Real Estate
- ABUS Health Care
- Exchange
- BFS Nasdaq
- ABUS Nasdaq
- Market Cap
- BFS 811.7M
- ABUS 711.2M
- IPO Year
- BFS 1993
- ABUS N/A
- Fundamental
- Price
- BFS $32.21
- ABUS $4.57
- Analyst Decision
- BFS
- ABUS Strong Buy
- Analyst Count
- BFS 0
- ABUS 2
- Target Price
- BFS N/A
- ABUS $5.00
- AVG Volume (30 Days)
- BFS 58.4K
- ABUS 1.5M
- Earning Date
- BFS 11-06-2025
- ABUS 11-05-2025
- Dividend Yield
- BFS 7.34%
- ABUS N/A
- EPS Growth
- BFS N/A
- ABUS N/A
- EPS
- BFS 1.32
- ABUS N/A
- Revenue
- BFS $277,902,000.00
- ABUS $15,416,000.00
- Revenue This Year
- BFS $10.48
- ABUS $138.02
- Revenue Next Year
- BFS $6.52
- ABUS N/A
- P/E Ratio
- BFS $24.35
- ABUS N/A
- Revenue Growth
- BFS 5.23
- ABUS 53.23
- 52 Week Low
- BFS $31.25
- ABUS $2.71
- 52 Week High
- BFS $42.39
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- BFS 40.14
- ABUS 68.75
- Support Level
- BFS $33.58
- ABUS $4.37
- Resistance Level
- BFS $32.46
- ABUS $5.10
- Average True Range (ATR)
- BFS 0.57
- ABUS 0.25
- MACD
- BFS -0.15
- ABUS 0.06
- Stochastic Oscillator
- BFS 13.68
- ABUS 64.33
About BFS Saul Centers Inc.
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.